Category: 16506-27-7

Heterologous SARS-CoV -2 vaccinations in patients with B-cell lymphoid malignancies was written by Ujjani, Chaitra;Greninger, Alexander L.;Shadman, Mazyar;Hill, Joshua A.;Lynch, Ryan C.;Warren, Edus H.;Gopal, Ajay K.. And the article was included in American Journal of Hematology in 2022.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

This article deals about heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies. The majority of patients subsequently received another mRNA vaccine for a total of four vaccinations. The median IgG, absolute lymphocyte count, and normal CD19+ B-cell counts were 597 mg/dL (range 180-1007), 0.97-103/mL (range 0.61-2.56), and 0.6 cells/mL (range 0-121), resp. Nucleocapsid antibody was nonreactive in all patients, indicating no evidence of prior SARS-CoV-2 infection. A number of variables such as type of B-cell directed therapy, length of and time from exposure, sequence of and duration between vaccinations, and underlying disease biol. may have had impact. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Recommanded Product: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Treatment strategy for patients with relapsed/refractory classical Hodgkin lymphoma was written by Yoshida, Isao. And the article was included in Ketsueki Naika in 2021.Related Products of 16506-27-7 The following contents are mentioned in the article:

A review. Classical Hodgkin lymphoma (CHL) is a type of lymphoma that is sensitive to chemotherapy and can provide an R-stage solution in many cases. Single-center pre-examination study of combination treatment with bendamustine, nivolumab for patients who became refractory to treatment with nivolumab. It will be performed in consideration of the disease, organ function, and the drug packing used in the previous treatment, but if the reduction effect is obtained by the rescue chemotherapy, the self-implantation combined large-scale chemotherapeutic method (ASCT) is used as a remedy treatment. This review outlines the treatment of relapsed/refractory classical Hodgkin lymphoma with a focus on brentuximab vedotin and ΡD-1 antibodies, and the usefulness of autologous stem cell transplant in therapeutic cases. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Related Products of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Related Products of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Reduced bendamustine for elderly patients with follicular lymphoma was written by Masamoto, Yosuke;Shimura, Arika;Kurokawa, Mineo. And the article was included in Annals of Hematology in 2022.Application of 16506-27-7 The following contents are mentioned in the article:

As the outcome of follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin’s lymphoma, has been improved since the introduction of immunochemotherapy, non-lymphoma-related causes of death, including infections, have become increasingly important. Bendamustine is widely used as one of the key drugs of the standard therapy, and characterized by long-term lymphocytopenia as a frequent adverse event, rendering the patients especially vulnerable to various infections. In this study, authors aims to clarify the short-term outcome and toxicities of the reduced bendamustine. Patients underwent bendamustine treatment without dose reduction from the original plan. Elderly patients in this cohort showed promising outcomes with a similar rate of toxicities except for lymphocytopenia. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Application of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy was written by Landsburg, Daniel J.;Nasta, Sunita D.;Gerson, James N.;Svoboda, Jakub;Chong, Elise A.;Schuster, Stephen J.;Barta, Stefan K.;Robinson, Kyle W.;Hughes, Mitchell E.. And the article was included in Leukemia & Lymphoma in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

Our study is also unique in reporting time-to clin. response. While clin. responses as defined in this anal. could only be achieved by patients who demonstrated defined clin. signs/symptoms at the start of PV-based therapy, the majority of those patients who achieved a clin. response and had a subsequent radiog. assessment also achieved a radiog. response, suggesting that clin. response, when detectable, may be an indicator of disease response in this patient population. In conclusion, patients with relapsed/refractory DLBCL/ HGBL treated at our center with PV, with or without concurrent rituximab and/or bendamustine, frequently achieved rapid and durable responses. These findings may inform clin. management as well as investigational study design for this patient population. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study was written by Wang, Xiao-Xiao;Gao, Yan;Jin, Jie;Cao, Jun-Ning;Feng, Ji-Feng;Wang, Hua-Qing;Zhang, Hui-Lai;Cai, Qing-Qing;Li, Zhi-Ming;Jiang, Wen-Qi;Huang, Hui-Qiang;on behalf of the Lymphoma Committee, Chinese Anti-Cancer Association. And the article was included in Annals of Hematology in 2021.SDS of cas: 16506-27-7 The following contents are mentioned in the article:

This study aimed to identify the maximum-tolerated dose (MTD) of cyclophosphamide when combined with bortezomib and fludarabine (B-FC) in a phase 1b trial, and to assess the efficacy and safety of this combination in a phase 2 trial in patients with relapsed or refractory MCL (rrMCL). Forty patients were enrolled between Apr. 8, 2011, and Oct. 10, 2015. The MTD of cyclophosphamide was identified to be 250 mg/m² days 1-2. At a median follow-up of 31.6 mo (13.5-47.4), among 32 patients in phase 2, 10 (31%) had a complete response and 13 (41%) had a partial response. The median progression-free survival was 21 mo (95% CI 7.3-34.7), and the median overall survival was 32.4 mo (95% CI 17.8-47.0). Grade 3-4 hematol. AEs included neutropenia (27%) and thrombocytopenia (39%). The B-FC regimen has satisfactory responses and manageable toxicities in rrMCL patients (ClinicalTrials.gov NCT01322776). This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7SDS of cas: 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.SDS of cas: 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Commentary: post-transplantation cyclophosphamide uniquely restrains alloreactive CD4+ T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation was written by Stokes, Jessica;Simpson, Richard J.;Katsanis, Emmanuel. And the article was included in Frontiers in Immunology in 2022.Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

Herein authors investigated whether post-transplant cyclophosphamide (PT-CY) is unique in protecting against graft-vs.-host disease (GvHD) by comparing it to multiple other ′′optimally dosed′â€?chemotherapeutics. They concluded that PT-CY was superior to all other agents in ameliorating both clin. and histopathol. GvHD. It discuss about post-transplantation cyclophosphamide which uniquely restrains alloreactive CD4+ T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation. Authors discuss on the use of post-transplant bendamustine (PT-BEN) as an alternative agent that could replace PT-CY. They demonstrated that PT-BEN was equally effective in preventing early GvHD and protecting against late GvHD, while enabling superior graft-vs.-leukemia (GvL), when compared to PT- CY in murine haploidentical bone marrow transplantation (haplo-BMT). This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Name: 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis was written by Khurana, Arushi;Dalland, Joanna C.;Young, Jason R.;Inwards, David J.;Paludo, Jonas. And the article was included in American Journal of Hematology in 2021.COA of Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:

The ZUMA-2 trial, however, excluded patients with a possible requirement for urgent therapy due to ongoing or impending oncol. emergency (eg, tumor mass effect, tumor lysis syndrome), involvement of the central nervous system and required patients to be exposed to a Bruton tyrosine kinase (BTK) inhibitor. Interim PET/CT after three cycles of bendamustine and rituximab, showed a significant improvement in lymphadenopathy and skeletal lesions, however, with new lesions in the nasopharynx and right chest wall. The patient underwent brexu-cel therapy after lymphodepletion chemo but his course was complicated by cytokine release syndrome (CRS) on day +1 with a peak grade of one based on the ASTCT 2019 grading. This is the first report of a brexu-cel for MCL-associated NL and blastoid variant with complete remission at day +60 without added neurotoxicity. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7COA of Formula: C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. COA of Formula: C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents was written by Shah, Harsh;Jang, Hyejeong;Singh, Paramveer;Kosti, Jorgena;Kin, Andrew;Alavi, Asif;Ratanatharathorn, Voravit;Ayash, Lois;Uberti, Joseph;Ramchandren, Radhakrishnan;Kim, Seongho;Deol, Abhinav. And the article was included in Leukemia & Lymphoma in 2022.Synthetic Route of C16H21Cl2N3O2 The following contents are mentioned in the article:

Utilization of novel agents such as brentuximab vedotin (BV) and check-point inhibitors (CI) has increased in patients with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL). We conducted a retrospective study of 209 patients who had ASCT for r/r cHL at our institution and compared outcomes of those who had ASCT from 2010-2018 (cohort 2, n = 110) with those who had ASCT between 2000 and 2009 (cohort 1, n = 99). The median OS was 7.6 years for cohort 1 [HR 2.08; 95% CI 1.14-3.80; p = 0.017] and not reached for cohort 2; with 4-yr improved OS difference of 15% (80% vs 65%) in cohort 2 vs cohort 1. The median PFS of cohort 1 was 30 mo vs 39 mo for cohort 2[HR 1.24; 95% CI 0.82-1.88; p = 0.3]. This study highlights improved OS of r/r cHL patients who have received ASCT in the novel agent era due to the exposure to agents such as BV and CIs. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Synthetic Route of C16H21Cl2N3O2).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is the basic core of some natural products such as histidine, purine, histamine and DNA based structures, etc. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. This ring system is present in important biological building blocks, such as histidine and the related hormone histamine.Synthetic Route of C16H21Cl2N3O2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma was written by Takakuwa, Teruhito;Okayama, Yusuke;Nakamae, Hirohisa;Kuno, Masatomo;Makuuchi, Yosuke;Harada, Naonori;Okamura, Hiroshi;Nishimoto, Mitsutaka;Nakashima, Yasuhiro;Koh, Hideo;Hino, Masayuki. And the article was included in Annals of Hematology in 2022.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid The following contents are mentioned in the article:

A case of ASCT performed following Pola-BR therapy for relapsed diffuse large B-cell lymphoma was reported. A 32-yr-old previously healthy man presented to hospital complaining of gradually worsening back pain that had first developed 3 mo earlier. Computed tomog. revealed multiple masses in the left liver lobe, pancreatic body, and both kidneys, as well as multiple enlarged lymph nodes. Based on the above findings, DLBCL stage IV was diagnosed. After six courses of R-CHOP, complete response (CR) was achieved, but back pain reoccurred 1 mo following treatment conclusion. Since a partial response was achieved after the first course of Pola-BR treatment, stem cell collection (SCC) at the conclusion of the second course was planned. MEAM (ranimustine, etoposide, cytarabine, and melphalan) with ASCT was subsequently performed and CR was achieved. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Application In Synthesis of 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Campylobacter infection in 4 patients treated with ibrutinib was written by Sorin, Boris;Vigneron, Julien;Fadlallah, Jehane;Mondesir, Johanna;Fieschi, Claire;Oksenhendler, Eric;Galicier, Lionel;Malphettes, Marion. And the article was included in European Journal of Clinical Microbiology & Infectious Diseases in 2022.Category: imidazoles-derivatives The following contents are mentioned in the article:

Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor used in B-cell lymphoproliferative disorders. Patients with genetic BTK deficiency are susceptible to recurrent and severe Campylobacter infections. We report 4 patients treated with ibrutinib who developed chronic or extra-digestive campylobacteriosis resembling ibrutinib-related adverse events including diarrhea (n = 4), panniculitis (n = 2), and arthritis (n = 1). Microbiol. explorations identified Campylobacter jejuni (n = 3) or Campylobacter coli (n = 1). All the patients completely recovered after a short course of oral antibiotic therapy. In patients treated with ibrutinib presenting with chronic diarrhea, dermatol., or rheumatol. manifestations, campylobacteriosis should be ruled out before attributing the symptoms to ibrutinib and discuss its discontinuation. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Category: imidazoles-derivatives).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Among the different heterocyclic compounds, imidazole is better known due to its broad range of chemical and biological properties. Imidazole has become an important synthon in the development of new drugs. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem